This sonofabitch should be in jail. He's been hyping PANW for months, sucking all the little guys in at the top, screaming how this cyber-security company was "best in breed." And now that we've all committed our cash to buying shares of this company, he comes on on a Friday night without warning and after the market is closed and hits the stock with a "Time to sell" command, driving the share price down in after-hours trading by four dollars in a nano-second and wiping out everybody's profits who got in over the last few weeks while he was still hitting the "Buy, Buy, Buy" button. No doubt, Cramer and his buddies must have started shorting the stock at the $108 level it reached today, just before he came on the air to tell everyone that the stock had gone up too far and "pigs get slaughtered." Cramer's "charitable trust," however, is doing just fine, I'd imagine, now that he's got even more of my money and the funds of thousands of other little suckers too. I'm tired of being burned by this little bald-headed creep and his nightly Soupy Sales clown routines on CNBC. I'm swearing off forever and never watching this snake-oil charlatan again. I hope the thousands of other suckers who watch his nightly antics and con game stop watching too and drive this cretin off the air for good.
Yet, ANSS’ low RSI value isn’t the only reason to have some optimism over a coming turnaround, as there has been plenty of positive earnings estimate revision activity as of late. This is especially true when investors take a deep dive into some of these estimate revision stats and recent changes to Ansys’ earnings consensus.
Over the past two months, investors have seen 3 earnings estimate revisions move higher, compared with none lower, at least when looking at the key current year time frame. And the consensus estimate for ANSS has also been on an upward trend over the past 60 days, as estimates have risen from $3.07/share two months ago to just $3.08/share right now.
If this wasn’t enough, Ansys also has a Zacks Rank #2 (Buy) which puts it into rare company among its peers. So, given all of these factors, investors may want to consider getting in on this stock now (or holding on), as there are some favorable trends that could bubble up for this stock before long.
"The U.S. Food and Drug Administration said on July 10 that the sNDA expanding Relistor's indication to include chronic non-cancer pain patients with OIC can be approved on the data previously submitted in that filing. The decision follows Salix's appeal of the agency's Complete Response Letter on the filing two years ago and an Advisory Committee convened by the FDA last month. Salix submitted to the agency on July 25 information required for final approval, and we expect a two-month review.
Salix has said it intends to meet with the FDA as soon as possible to discuss a path forward for oral Relistor for the treatment of OIC in patients with chronic, non-cancer pain.
Results from two trials of the Company's small molecule PSMA imaging agent for prostate cancer, 1404, are scheduled to be presented at a featured oral session during the annual meeting of the European Association of Nuclear Medicine (EANM) in Gothenburg, Sweden on in October.
The phase 2 complete study results involving 104 patients are to be presented by Dr. Gabriella Dabasi of Semmelweis University.
Dr. Shankar Vallabhajosula of Cornell University's Medical College is to present phase 1 pilot study results on nine patients."
Ignorant heard mentality, confusion, or what?
5:01 pm Salix Pharma to combine with Cosmo Technologies; transaction expected to be modestly accretive to EPS in 2016 (stock halted) (SLXP) : Co and Cosmo Pharmaceuticals announced a definitive merger agreement under which Salix will combine with Cosmo Technologies Limited, a subsidiary of Cosmo. Under the terms of the agreement, Salix will become a wholly-owned subsidiary of Irish domiciled Cosmo Tech, which will change its name to Salix Pharmaceuticals, plc and is expected to have its ordinary shares listed and traded on the NASDAQ Global Select Market. The transaction is expected to be modestly accretive to Salix's earnings per share in 2016 and increasingly accretive thereafter.
Salix Pharmaceuticals, plc will own Cosmo's U.S. patents for rifamycin MMX, methylene blue MMX and Uceris, and have specified rights of negotiation with respect to all products Cosmo or its affiliates seek to develop or commercialize in the U.S. In addition, Salix Pharmaceuticals, plc will acquire Cosmo's patents for rifamycin MMX in Canada, specified Latin American countries, India, China, Japan and the rest of the Far East, excluding Australia and New Zealand, and Cosmo's patents for Uceris in Japan.
Upon completion of the merger, shareholders of Salix are expected to own slightly less than 80% of the ordinary shares of Salix Pharmaceuticals, plc and Cosmo is expected to own slightly more than 20%. Shareholders of Salix will receive one ordinary share of Salix Pharmaceuticals, plc in exchange for each share of Salix Pharmaceuticals, Ltd common stock they own at closing. In connection with the merger, Cosmo will continue to supply Uceris to Salix and will also supply rifamycin MMX and methylene blue MMX. Additionally, Cosmo will have the right to designate one director to serve on the board of directors of Salix Pharmaceuticals, plc and will be subject to certain standstill provisions for at least 10 years following the completion of the merger. The transaction, which will be taxable to Salix's shareholders, is expected to close in the fourth quarter of 2014.
In connection with the transaction, Salix will also receive certain rights and protections under a Right of Negotiation and Non-Compete Agreement, which will: (1) give Salix a right of first negotiation with respect to all future products Cosmo or its affiliates seek to market in the U.S. in the GI space, and (2) prohibit Cosmo from competing directly with the combined company in the GI space in the U.S. These terms will apply as long as Cosmo is entitled to designate a director to serve on the board of directors of Salix Pharmaceuticals, plc.